MedPath

The Use of Transcranial Direct Current Stimulation (tDCS) in Adults with Developmental Disabilities

Not Applicable
Recruiting
Conditions
Aggression
Interventions
Device: Transcranial Direct Current Stimulation
Registration Number
NCT04732052
Lead Sponsor
Dr. Najat Khalifa
Brief Summary

Aggressive behaviours are highly prevalent among people with developmental disabilities, both in community and inpatient or residential settings, with adverse consequences for the individuals involved and others. Some predictive factors, particularly impulsivity, are dynamic with neurobiological underpinnings, and as such amenable to change or neuromodulation using non-invasive brain stimulation techniques. With this in mind, we designed an experimental protocol to determine the efficacy of transcranial Direct Current Stimulation (tDCS) as a non-invasive brain stimulation technique to reduce impulsivity and aggression associated with developmental disability.

Detailed Description

This study aims to assess the efficacy of anodal tDCS in modulating Rapid Response Impulsivity (RRI) and reducing incidents of aggression in people with developmental disabilities is residential or hospital settings. Using a single blind, parallel arms, randomized controlled trial design, adults (n=60) aged 18 to 65 with developmental disabilities, who have a history of impulsivity leading to aggression, will be randomised to receive either repetitive anodal or sham tDCS. Enrolled participants will receive either three treatment sessions of tDCS or sham tDCS. Behavioural and impulsivity will be measured before and immediately after treatment, one week, and one month after treatment end. Data will be analysed in SPSS using repeated measures ANOVA.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Adults aged 18-64 years
  • Diagnosis of a developmental disability
  • History of one or more incidents of aggression in the last month
  • Consent to participate in the trial by the individual or their Substitute Decision Maker
Exclusion Criteria
  • History of epilepsy or seizures
  • History of acquired brain injury
  • Having metal in the brain/skull, e.g. splinters, fragments or clips
  • Having a cochlear implant
  • Having an implanted neuro-stimulator (e.g. direct brain stimulation, epidural/subdural stimulation, vagal nerve stimulation)
  • History of brain surgery of procedure
  • History of severe adverse reaction to tDCS
  • Having a cardiac pacemaker or intracardiac lines
  • Current alcohol or drug misuse
  • Having a sensitive scalp

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Active tDCSTranscranial Direct Current StimulationTranscranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the stimulation using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The active stimulation condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration a single tDCS session will be 20 minutes.
Sham tDCSTranscranial Direct Current StimulationSham Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the sham stimulation using two sponge electrodes soaked in a saline solution. The sham stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation for 10s only. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The sham tDCS is identical to the active tDCS except that the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each sham tDCS session will be 20 minutes.
Primary Outcome Measures
NameTimeMethod
Aggressionchange from baseline one week and one month after the third tDCS session

To determine the effect of tDCS treatment on aggressive symptoms measured by The Modified Overt Aggression Scale (MOAS); Total weighted scores range from 0-40, with a higher score indicating more aggressive behavior.

Secondary Outcome Measures
NameTimeMethod
Intervention side effectsUp to 72hrs after the first, second, and third active or sham tDCS treatments.

Tracking potential side effects of tDCS/sham treatments using tDCS adverse effects questionnaire.

Maladaptive behaviorschange from baseline one week and one month after the third tDCS session

Behavior Problems Inventory (BPI); The total frequency scores range from 0-120 and severity of self-injurious behaviour and aggression subscales from 18-54, with higher scores indicating higher frequency and severity

Trait ImpulsivityBaseline

Barratt Impulsiveness Scale-11 (BIS-11); The total scores range from 30 - 120, with higher scores indicating higher impulsivity.

Treatment AcceptabilityUp to 72hrs after the third active or sham tDCS treatments.

Total scores on the tDCS Treatment Acceptability Questionnaire

Impulsivitychange from baseline and the same day after the third tDCS sessions

To determine the effects of tDCS treatment on symptoms of impulsivity measured by the Stop Signals Task (SST)

Trial Locations

Locations (1)

Providence Care Hospital

🇨🇦

Kingston, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath